2. Study to assess adverse events and change in disease activity in adult participants with advanced solid tumors receiving intravenous (IV) ABBV-400 as monotherapy and in combination with IV bevacizumab. ClinicalTrials.gov. Updated July 15, 2024. Accessed July 31, 2024.发布...
一项1期试验(NCT05029882)的数据显示,靶向c-Met的新型ADC药物ABBV-400在BRAF野生型、微卫星稳定型(MSS)/错配修复良好型(pMMR)晚期结直肠癌(CRC)患者中显示出初步的抗肿瘤活性,且患者耐受性良好。港安健康国际医疗介绍,ABBV-400将c-Met靶向抗体telisotuzumab与拓扑异构酶1抑制剂有效载荷相结合。c-Met的过表达在...
The study is also evaluating ABBV-400 with bevacizumab in pts with CRC.Clinical trial information: NCT05029882.Preliminary efficacy outcomes.CRC Dosing Cohorts1.6 mg/kg Q3W(n = 32)2.4 mg/kg Q3W(n = 40)3.0 mg/kg Q3W(n = 41)Confirmed ORR, n (%)06 (15)8 (20)CBR12, n (%)11 (...
For research use only. Not suitable for clinical or therapeutic use. Aiming to develop the most reliable bioreagents, AntibodySystem SAS was founded in 2019 in France by a team of professionals from top industrial companies and research institutes. The collective scientific and technical experiences ...
(ORR); while the 3.0 mg/kg dose may provide higher response rates, the 2.4 mg/kg Q3W dosing regimen provides an optimal balance of safety and efficacy compared to 3.0 mg/kg Q3W.Conclusions:Population PK, E-R for efficacy and safety and RDI analyses and totality of clinical data supported...
Carla Biesdorf de AlmeidaAbbVie Inc., North Chicago, ILAthanasios VasilopoulosAbbVie Inc., North Chicago, ILYunxia SuiAbbVie Inc., North Chicago, ILJohn H StricklerDuke University School of Medicine, Durham, NCAmerican Society of Clinical OncologyJournal of Clinical Oncology...
Athanasios VasilopoulosAbbVie Inc., North Chicago, ILGladys Morrison ThieleAbbVie Inc., North Chicago, ILMichael Charles BurnsAbbVie Inc., North Chicago, ILJames J. HardingMemorial Sloan Kettering Cancer Center, New York, NYAmerican Society of Clinical OncologyJournal of Clinical Oncology...